buyNotable

Charles D. Goodwin II bought $79k of APYX

Chief Executive Officer at Apyx Medical Corp. 50,000 shares at an average of $1.57, traded Nov 14, 2023, filed Nov 15, 2023.

Conviction score

Value

$79k

50,000 shares

Holdings after

90,000

+125% from before

From 52-week low

+7%

low $1.40, close $1.50

From 52-week high

-80%

high $7.59, as of Nov 14, 2023

Score components

Role
CEO
+25
Trade size
$78k at market
+9
Relative to holdings
Holdings up 125%
+10
Price context
7% above the 52-week low; 80% below the 52-week high
+18
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (0 with prices)
0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +57.7%, 3m +64.4%, 6m -5.4%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

APYXOct 13, 2026 · close 2.60

Since filing Nov 15, 2023: +74.5%SPY +79.4% · excess -4.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001493152-23-041501, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Nov 14, 2023	POpen-market purchase Common Stock	+50,000	$1.57	$79k	90,000	Nov 15, 2023

Related signals

Other insiders at Apyx Medical Corp and this insider’s other filings.

Score	Company	Insider	Value	Holdings	Filed
50Moderate	APYXbuy Apyx Medical Corp	Matthew C Hill Chief Financial Officer	$6,030 5,336 shares	+213%	Aug 13, 2024
38Weak	APYXbuy Apyx Medical Corp	Matthew C Hill Chief Financial Officer	$5,475 2,500 shares	-	Dec 14, 2023

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.